$3.77
-0.48 (-11.20%)
Open$4.24
Previous Close$4.24
Day High$4.29
Day Low$3.76
52W High$5.55
52W Low$2.65
Volume—
Avg Volume518.3K
Market Cap256.19M
P/E Ratio—
EPS$-1.98
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+1,133.5% upside
Current
$3.77
$3.77
Target
$46.44
$46.44
$29.94
$46.44 avg
$64.67
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 46.81M | 47.01M | 42.57M |
| Net Income | -138,796,443 | -125,456,260 | -129,666 |
| Profit Margin | -296.5% | -281.7% | -0.3% |
| EBITDA | -146,233,668 | -139,521,928 | -158,434 |
| Free Cash Flow | — | — | -114,389 |
| Rev Growth | -0.4% | -0.4% | +21.1% |
| Debt/Equity | — | — | 0.31 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |